Mantle Cell Lymphoma Market

Market Overview:

The 7 major mantle cell lymphoma markets reached a value of US$ 1.6 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2.9 Billion by 2034, exhibiting a growth rate (CAGR) of 5.76% during 2024-2034.

The mantle cell lymphoma market has been comprehensively analyzed in IMARC's new report titled "Mantle Cell Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Mantle cell lymphoma (MCL) refers to an aggressive, rare kind of B-cell non-Hodgkin lymphoma that arises in the white blood cells of the lymph nodes, bone marrow, and other tissues. Depending on the causative factor and extent of the disease, MCL is categorized into nodal and leukemic non-nodal mantle cell lymphoma. The most common symptoms of this ailment include fevers, lower back pain, night sweats, loss of appetite and weight, unexplained itching, swollen lymph nodes in the neck, armpits, or groin, nausea, vomiting, fatigue, heartburn, etc. Additionally, patients may also experience bloating, diarrhea, or abdominal pain if the lymphoma affects the gastrointestinal region. The diagnosis usually requires a combination of medical history, blood tests, and laboratory studies. Various other investigations, such as positron emission tomography (PET) scan, computed tomography (CT) scan, polymerase chain reaction, etc., are also utilized to confirm the prognosis. Besides this, the healthcare professional may perform an excisional biopsy of the lymph node to validate the disease staging in the patient.

The increasing cases of genetic disorders due to gene alteration and overexpression, resulting in abnormal proliferation of cancer cells, are primarily driving the mantle cell lymphoma market. Apart from this, the expanding geriatric population, who are more susceptible to certain infections owing to weakened immune systems, is also bolstering the market growth. Additionally, the widespread adoption of immune-based therapies, which strengthen the patient's defense system to destroy lymphoma cells and retard their development, is creating a positive outlook for the market. Besides this, the inflating usage of Fluorescence In-situ Hybridization (FISH) for diagnosing the ailment on account of its several benefits, such as a better understanding of chromosomal abnormalities and genetic mutations with high specificity and sensitivity, is also augmenting the market growth. Moreover, the emerging popularity of BTK inhibitors, including ibrutinib and acalabrutinib, for targeting specific proteins or genes involved in the development and spread of cancer cells is further acting as another significant growth-inducing factor. In addition to this, the escalating demand for radioimmunotherapy to treat MCL, since it offers more personalized therapy against unhealthy cells and limits radiation exposure to normal tissue, is expected to drive the mantle cell lymphoma market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the mantle cell lymphoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for mantle cell lymphoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the mantle cell lymphoma market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the mantle cell lymphoma market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the mantle cell lymphoma market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current mantle cell lymphoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the mantle cell lymphoma market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the mantle cell lymphoma market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the mantle cell lymphoma market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of mantle cell lymphoma across the seven major markets?
• What is the number of prevalent cases (2018-2034) of mantle cell lymphoma by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of mantle cell lymphoma by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with mantle cell lymphoma across the seven major markets?
• What is the size of the mantle cell lymphoma patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of mantle cell lymphoma?
• What will be the growth rate of patients across the seven major markets?
   

Mantle Cell Lymphoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for mantle cell lymphoma drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the mantle cell lymphoma market?
• What are the key regulatory events related to the mantle cell lymphoma market?
• What is the structure of clinical trial landscape by status related to the mantle cell lymphoma market?
• What is the structure of clinical trial landscape by phase related to the mantle cell lymphoma market?
• What is the structure of clinical trial landscape by route of administration related to the mantle cell lymphoma market?